These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7353345)

  • 1. Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients.
    Bjornsson TD; Meffin PJ; Peters FA; Blaschke TF
    Clin Pharmacol Ther; 1980 Feb; 27(2):230-5. PubMed ID: 7353345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
    Merk W; Graben N; Hartmann H; Nikolaus C; Schlierf G; Schwandt P
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):59-62. PubMed ID: 3557732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.
    Robertz GM; Dengler HJ
    Klin Wochenschr; 1983 Jul; 61(13):649-53. PubMed ID: 6688447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
    Lacour B; Di Giulio S; Nicolaï A; Drüeke T; Debray M; Boulu RG
    Nephrologie; 1982; 3(1):19-22. PubMed ID: 7088259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-pressure liquid chromatographic analysis of drugs in biological fluids. IV. Determination of clofibrinic acid.
    Bjornsson TD; Blaschke TF; Meffin PJ
    J Chromatogr; 1977 Jul; 137(1):145-52. PubMed ID: 893579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of clofibrate in patients with renal insufficiency.
    Viikari J; Anttila M; Kasanen A
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.
    Verbeeck RK; De Schepper PJ
    Clin Pharmacol Ther; 1980 May; 27(5):628-35. PubMed ID: 7371361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hyperbilirubinaemia on the plasma protein binding of chlorophenoxyisobutyric acid in neonates.
    Barré J; Houin G; Shastri RA; Benattar C; Lindenbaum A; Tillement JP
    Dev Pharmacol Ther; 1984; 7 Suppl 1():26-9. PubMed ID: 6518967
    [No Abstract]   [Full Text] [Related]  

  • 9. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
    Meffin PJ; Zilm DM
    J Chromatogr; 1983 Nov; 278(1):101-8. PubMed ID: 6662867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of creatinine levels in saliva and plasma in normal subjects and renal patients.
    Chiou WL; Hsu FH; Westenfelder C; Kurtzman NA
    Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):549-56. PubMed ID: 847302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
    Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
    PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S; Boulu R; Drüeke T; Nicolaĭ A; Zingraff J; Crosnier J
    Clin Nephrol; 1977 Dec; 8(6):504-9. PubMed ID: 598055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma aminothiol oxidation in chronic hemodialysis patients.
    Himmelfarb J; McMenamin E; McMonagle E
    Kidney Int; 2002 Feb; 61(2):705-16. PubMed ID: 11849414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous GLC determination of clofibrate and clofibric acid in human plasma.
    Wolf MS; Zimmerman JJ
    J Pharm Sci; 1980 Jan; 69(1):92-3. PubMed ID: 7354454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products.
    Altmayer P; Garrett ER
    J Pharm Sci; 1983 Nov; 72(11):1309-18. PubMed ID: 6644594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of clofibrate toxicity in uremic hypertriglyceridemia.
    Goldberg AP; Sherrard DJ; Haas LB; Brunzell JD
    Clin Pharmacol Ther; 1977 Mar; 21(3):317-25. PubMed ID: 837651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impaired plasma protein binding of furosemide in nephrotic syndrome and uremia].
    Takahashi F
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):665-80. PubMed ID: 7176178
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis.
    Losno Garcia R; Santivañez V; Battilana CA
    Chemotherapy; 1988; 34(4):261-6. PubMed ID: 3208543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.